Santarus (SNTS) 4.86 -0.135

Santarus, Inc.
(SNTS) 4.86 -0.135

Last Trade:	4.865	Day Range:	4.84 - 4.97
Trade Time:	08:02PM	52wk Range:	2.40 - 5.10
Prev. Close:	5.00	Market Cap:	296.14M
Open:	4.95	Div Yield:	0
Volume:	360305	PE:
EPS:	0.01

The Latest On SNTS

From Earlier: Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE 2/6/12 7:16am

Weekly Homework: When Will Bonds Unravel? (w/ Economic Calendar & Stock Radar) 1/16/12 11:35pm

Potential Trades With Charts: Markets Refuse To Pullback 1/9/12 11:32pm

Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar) 1/2/12 8:38pm

End-of-Day Market Summary for December 20, 2011 12/20/11 4:20pm

Santarus Submits New Drug Application to FDA for UCERIS Tablets 12/20/11 4:15pm

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11 11:28pm

Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress 12/7/11 7:20am

Santarus Announces Presentation of Pooled Data from Budesonide MMX Phase III Clinical Studies at the ACG Annual Scientific Meeting 11/1/11 5:40am

Santarus and Depomed Announce New U.S. Commercialization Agreement for GLUMETZA Prescription Products 8/22/11 5:47am

Santarus and Pharming Announce Special Protocol Assessment Agreement with FDA for RHUCIN Phase III Clinical Study 8/4/11 5:53am

Hearing Twitter Chatter Santarus Cancels Upcoming Biotech Conference Appearance 7/6/11 2:04pm

From Earlier: Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE 2/6/12

Weekly Homework: When Will Bonds Unravel? (w/ Economic Calendar & Stock Radar) 1/16/12

Potential Trades With Charts: Markets Refuse To Pullback 1/9/12

Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar) 1/2/12

End-of-Day Market Summary for December 20, 2011 12/20/11

Santarus Submits New Drug Application to FDA for UCERIS Tablets 12/20/11

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11

Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress 12/7/11

Santarus Announces Presentation of Pooled Data from Budesonide MMX Phase III Clinical Studies at the ACG Annual Scientific Meeting 11/1/11

Santarus and Depomed Announce New U.S. Commercialization Agreement for GLUMETZA Prescription Products 8/22/11

Santarus and Pharming Announce Special Protocol Assessment Agreement with FDA for RHUCIN Phase III Clinical Study 8/4/11

Hearing Twitter Chatter Santarus Cancels Upcoming Biotech Conference Appearance 7/6/11

Weekly Homework: When Will Bonds Unravel? (w/ Economic Calendar & Stock Radar) 1/16/12

Potential Trades With Charts: Markets Refuse To Pullback 1/9/12

Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar) 1/2/12

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11

Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD) 9/30/10

News Summary (EEP, NSM, TXN, SNTS) 9/10/10

Mid-Day Market Movers (BDCO, PRPH, SNTS, FCFL) 9/9/10

SNTS Shares Up After Exclusive US Rights For Cycloset 9/9/10

Benzinga’s Top Pre-Market Losers (SNTS, REVU, TITN, SMOD) 4/15/10

Benzinga’s Top Pre- Market Gainers (SNTS, AKAM, NVDA, AGU, MDR, SPWRA) 12/7/09

End-of-Day Market Summary for December 20, 2011 12/20/11

Piper Jaffray Neutral On Santarus (SNTS) 12/1/10

Piper Jaffray Sees Commerical Risk For Budesonide MMX 9/30/10

Piper Jaffray Reiterates Neutral Rating On Santarus (SNTS) 8/3/10

Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS 12/2/09

Flurry Of Upcoming Events Could Trigger Santarus Shares Over Next 2-3 Months 11/24/09

Trade SNTS
NOW!

Partner Headlines

5 Stocks Hitting New 52-Week Highs 1/11/12

SuperGen - Upgrades & Downgrades 3/4/11

SAP, Oracle: Premarket Trading 12/29/10

Fuqi Down on SEC Probe; Symantec Steady 9/8/10

Trico Marine Services, Sequenom: Early Volume Plays 5/7/10

Dynavax, Santarus: Early Volume Plays 4/15/10

Press Releases

Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE 2/6/12 Business Wire Story

Santarus Adds FENOGLIDE to Marketed Products Portfolio 12/21/11 Business Wire Story

Santarus Submits New Drug Application to FDA for UCERIS (budesonide) Tablets 12/20/11 Business Wire Story

Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress 12/7/11 Business Wire Story

Santarus Announces Presentation of New Open-Label UCERIS (Budesonide) Data at the Crohn's and Colitis Foundation Clinical & Research Conference 12/1/11 Business Wire Story

Santarus to Present at November Investment Conferences 11/8/11 Business Wire Story

Santarus Reports Third Quarter 2011 Financial Results 11/7/11 Business Wire Story

Santarus and Pharming Announce Presentation of Retrospective Analyses of Data from Clinical Studies of RHUCIN 11/4/11 Business Wire Story

Santarus Announces Presentation of Pooled Data from Budesonide MMX Phase III Clinical Studies at the ACG Annual Scientific Meeting 11/1/11 Business Wire Story

Santarus Reports Second Quarter 2011 Financial Results 8/30/11 Business Wire Story

Santarus Announces Supportive Top-Line Results from Budesonide MMX Extended Use Study 8/30/11 Business Wire Story

Santarus and Depomed Announce New U.S. Commercialization Agreement for GLUMETZA Prescription Products 8/30/11 Business Wire Story

Get the latest SNTS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Santarus, Inc. stock price.

Santarus, Inc. by YCharts

Santarus (SNTS) 4.86 -0.135

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On SNTS

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social